Last updated: February 27, 2026
What is NDC 00904-7087?
NDC 00904-7087 refers to Ondansetron ODT (orally disintegrating tablet), marketed under the brand name Zofran ODT. It is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery.
Market Overview
Market Size and Demand Drivers
- Global antiemetic market estimated at USD 1.7 billion in 2022.
- Compound annual growth rate (CAGR) of 4.8%, projected to reach USD 2.4 billion by 2030 [1].
- Ondansetron constitutes approximately 35-40% of antiemetics used in oncology settings.
Key Market Segments
- Oncology patients receiving chemotherapy.
- Postoperative patients undergoing surgery.
- Patients receiving radiotherapy.
Geographic Distribution
| Region |
Market Share (2022) |
Growth Rate (2023-2030) |
| North America |
45% |
3.9% |
| Europe |
28% |
4.5% |
| Asia-Pacific |
15% |
6.2% |
| Others |
12% |
4.8% |
Major players include GlaxoSmithKline (Zofran brand), Apotex, Teva, and Mylan.
Competition Landscape
| Competitor |
Product |
Formulation Type |
Market Share |
Pricing Strategy |
| GlaxoSmithKline |
Zofran ODT |
ODT |
60% |
Premium pricing, patent protection in place until 2025 |
| Teva |
Ondansetron tabs |
Tablets |
20% |
Competitive, generic options |
| Mylan |
Ondansetron syrup |
Syrup |
10% |
Lower-cost alternative |
| Others |
Various generics |
ODT, tablets, syrup |
10% |
Price-sensitive markets |
Patent and Regulatory Status
- Original patent expired in 2016.
- Zofran ODT has patent protection until 2025 in the U.S., after which generic versions dominate.
Price Projections
Current Pricing Trends
| Formulation |
Price per unit (USD) |
Discounted Price (USD) in generics |
Price Premium (Brand vs. Generic) |
| Zofran ODT (30 mg) |
$15-$20 |
$8-$12 |
50-75% |
| Generic Ondansetron (30 mg) |
$7-$10 |
N/A |
N/A |
Future Price Trends (Next 5 Years)
- Post-2025, generic competition will reduce prices by an additional 25-35%.
- Brand Zofran ODT could maintain a price premium of 40-50% until patent expiration.
- Forecasted average price per unit of generics in 2028: USD 5–8.
Market Penetration Impact
- As patent expiration approaches, substantial shift toward generics is expected.
- Price erosion in branded formulations could reach 60% within three years of patent expiry.
- Institutional purchasing and insurance negotiations will influence actual patient prices.
Factors Influencing Pricing and Market Share
- Patent expiry timeline (2025 for Zofran ODT).
- Regulatory approvals in emerging markets.
- Prescriber preferences for branded versus generic.
- Insurance reimbursements and formulary placements.
- Manufacturing costs and supply chain stability.
Key Considerations for Investment or R&D
- The expiration of patent protection in 2025 signals a shift toward generic dominance.
- Development of newer formulations or combination therapies may extend market exclusivity.
- Entry barriers, manufacturing capabilities, and regulatory pathways influence competitive positioning.
Key Takeaways
- NDC 00904-7087 (Ondansetron ODT) is a significant drug within the antiemetic market, primarily driven by oncology applications.
- Market size was USD 1.7 billion in 2022, growing at approximately 4.8% annually.
- Patent expiration in 2025 will lead to increased generic competition and price declines.
- Brand premium prices are forecasted to diminish as generics enter the market, with prices potentially decreasing by 60%–70% within three years post-patent expiry.
- Market share will shift toward generics, with price negotiations and regulatory policies significantly impacting pricing and adoption.
FAQs
Q1: When does the patent for Zofran ODT expire?
A1: The patent is set to expire in 2025.
Q2: How will generic competition affect prices?
A2: Prices of generic ondansetron formulations are expected to decrease by 25-35% shortly after patent expiry and could decline further within three years.
Q3: What are the primary markets for ondansetron?
A3: Oncology chemotherapy, radiotherapy, and postoperative nausea management.
Q4: Which companies hold the majority of market share?
A4: GlaxoSmithKline (Zofran) holds the largest share, followed by Teva and Mylan with generics.
Q5: Are there new formulations or delivery methods expected?
A5: Innovation includes dissolvable tablets, liquid formulations, and combinations but none are expected to significantly alter market dynamics before patent expiration.
References
[1] MarketResearch.com. (2022). Global Anti-emetic Drugs Market. Retrieved from https://www.marketresearch.com/
